Earnings call transcript: Cimpress reports Q4 2025 earnings miss, stock rises

Cimpress NV reported a significant Q4 2025 EPS miss of -$1.02 against a $0.98 forecast, yet shares surged 12.45% after-hours, driven by a revenue beat of $869.48 million (vs. $844.24M expected) and strong sales performance in higher-growth "elevated product categories." Despite a 110 basis point gross margin compression due to product mix shift, consolidated revenue grew 4% (2% organic constant currency), and contribution profit rose 5%. Management's aggressive share buybacks and a positive FY26 outlook, projecting 5-6% revenue growth and at least $450 million in Adjusted EBITDA, underscore investor confidence in the company's strategic transition and long-term investments despite increased CapEx impacting near-term free cash flow conversion.

Analysis

Cimpress NV demonstrated a narrative divergence in its Q4 2025 results, where a significant earnings per share miss of -1.02 USD against a 0.98 USD forecast was overshadowed by positive operational and strategic indicators, catalyzing a 12.45% after-hours stock increase. The market's positive reaction was driven by a 2.99% revenue beat to 869.48 million USD and clear evidence of a successful strategic pivot. The company is transitioning from mature legacy products, such as business cards which declined 6% in Q4, to higher-growth "elevated product categories" like promotional products, apparel, and gifts, which collectively grew 18% for the fiscal year on a base exceeding 300 million USD. While this product mix shift compressed gross margins by 110 basis points, underlying profitability improved, with contribution profit growing 5%. Management has reinforced its confidence through aggressive share buybacks and issued a strong FY26 outlook, projecting 5-6% revenue growth, at least 450 million USD in adjusted EBITDA, and approximately 140 million USD in adjusted free cash flow. This guidance incorporates a heavy investment cycle, with planned capital expenditures and capitalized software totaling approximately 170 million USD, which is expected to yield 70 to 80 million USD in incremental annualized EBITDA by FY27 but will suppress near-term free cash flow conversion.

Key Decisions for Investors

• Investors should prioritize the company's strategic transition and forward guidance over the headline Q4 EPS miss, as the positive stock reaction indicates the market is focused on the successful pivot to higher-growth product lines and strong FY26 EBITDA targets.
• Monitor the growth of 'elevated product' revenue and contribution profit as the most relevant indicators of operational health, given that gross margin will be temporarily distorted by the ongoing product mix shift.
• Factor in the aggressive share repurchase program as a strong signal of management's view that the stock is undervalued, but remain cognizant that near-term free cash flow will be constrained by the elevated investment cycle aimed at driving significant EBITDA growth by FY27.
• Assess the company's ability to continue mitigating tariff impacts through pricing and sourcing, as this remains a key variable, though management has incorporated this uncertainty into its otherwise confident forward-looking guidance.